Astria Therapeutics Inc
ATXS6.795USD
+0.235+3.58%
交易中 （美东）报价延迟15分钟
383.46M总市值
亏损市盈率 TTM
关于 Astria Therapeutics Inc 公司
Astria Therapeutics, Inc. 是一家专注于开发过敏和免疫疾病疗法的生物制药公司。该公司的领先项目 STAR-0215 是一种单克隆抗体血浆激肽释放酶抑制剂，目前正在临床开发中，用于治疗遗传性血管性水肿 (HAE)，这是一种罕见、使人衰弱且可能危及生命的疾病。其第二个项目 STAR-0310 是一种单克隆抗体 OX40 拮抗剂，目前正在临床前开发中，用于治疗特应性皮炎 (AD)。该公司拥有两个针对 STAR-0215 的专利家族。第一个专利家族针对其候选产品 STAR-0215 的物质组成及其在治疗包括 HAE 在内的各种血浆激肽释放酶相关疾病中的用途。在第二个专利系列中，该公司拥有一项国际（PCT）专利申请，针对使用 STAR-0215 抗体的特定给药方案治疗各种血浆激肽释放酶相关疾病（包括 HAE）的方法。
公司简介
公司代码ATXS
公司名称Astria Therapeutics Inc
上市日期Jun 25, 2015
CEODr. Jill C. Milne, Ph.D.
员工数量78
证券类型Ordinary Share
年结日Jun 25
公司地址22 Boston Wharf Road
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02210
电话16173491971
网址https://astriatx.com/
公司代码ATXS
上市日期Jun 25, 2015
CEODr. Jill C. Milne, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
Mr. Andrew Komjathy
Mr. Andrew Komjathy
Chief Commercial Officer
Chief Commercial Officer
--
--
Dr. Sunil Agarwal, M.D.
Dr. Sunil Agarwal, M.D.
Independent Director
Independent Director
--
--
Mr. Benjamin Scott Harshbarger
Mr. Benjamin Scott Harshbarger
Chief Legal Officer
Chief Legal Officer
--
--
Ms. Andrea Matthews
Ms. Andrea Matthews
Chief Business Officer
Chief Business Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Jonathan Violin, Ph.D.
Dr. Jonathan Violin, Ph.D.
Independent Director
Independent Director
263.32K
--
Mr. Noah Clauser
Mr. Noah Clauser
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Elizabeth Higgins
Ms. Elizabeth Higgins
Investor Relations
Investor Relations
--
--
Dr. Joanne T. Beck, Ph.D.
Dr. Joanne T. Beck, Ph.D.
Independent Director
Independent Director
--
--
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Mr. Gregg A. Lapointe, CPA
Mr. Gregg A. Lapointe, CPA
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
Perceptive Advisors LLC
11.49%
RA Capital Management, LP
9.05%
Fidelity Management & Research Company LLC
8.52%
Vestal Point Capital, LP
7.41%
Forbion Capital Partners
6.77%
Other
56.77%
持股股东
持股股东
占比
Perceptive Advisors LLC
11.49%
RA Capital Management, LP
9.05%
Fidelity Management & Research Company LLC
8.52%
Vestal Point Capital, LP
7.41%
Forbion Capital Partners
6.77%
Other
56.77%
股东类型
持股股东
占比
Investment Advisor
32.69%
Venture Capital
23.81%
Hedge Fund
19.93%
Investment Advisor/Hedge Fund
16.86%
Private Equity
11.49%
Research Firm
1.00%
Individual Investor
0.49%
Pension Fund
0.21%
Bank and Trust
0.19%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
263
60.20M
106.68%
-10.73M
2025Q1
281
59.08M
104.77%
-12.46M
2024Q4
268
59.35M
105.17%
-9.44M
2024Q3
247
57.14M
101.27%
-10.09M
2024Q2
228
56.25M
102.41%
-8.30M
2024Q1
210
58.30M
106.65%
+7.30M
2023Q4
179
37.20M
102.69%
+9.26M
2023Q3
171
23.97M
88.11%
-4.33M
2023Q2
175
25.83M
94.82%
-888.95K
2023Q1
166
24.59M
91.65%
-670.60K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Perceptive Advisors LLC
6.49M
11.49%
--
--
Mar 31, 2025
RA Capital Management, LP
5.11M
9.05%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
4.81M
8.52%
-846.00K
-14.97%
Mar 31, 2025
Vestal Point Capital, LP
4.18M
7.41%
--
--
Mar 31, 2025
Forbion Capital Partners
3.82M
6.77%
+950.00K
+33.07%
Mar 31, 2025
Fairmount Funds Management LLC
3.55M
6.3%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.40M
6.03%
-66.23K
-1.91%
Mar 31, 2025
Millennium Management LLC
2.94M
5.21%
+1.30M
+79.78%
Jun 13, 2025
TCG Crossover Management, LLC
2.76M
4.89%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.64M
4.68%
-29.10K
-1.09%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.86%
ALPS Medical Breakthroughs ETF
0.2%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.86%
ALPS Medical Breakthroughs ETF
占比0.2%
iShares Micro-Cap ETF
占比0.05%
ProShares Ultra Nasdaq Biotechnology
占比0.03%
Invesco Nasdaq Biotechnology ETF
占比0.03%
iShares Biotechnology ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.02%
Avantis US Small Cap Equity ETF
占比0.02%
iShares Russell 2000 ETF
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
公告日期
类型
比率
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
Aug 19, 2021
Merger
6<1
